| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00003910 Details | 2023-07-05 Interventional | 2 | 59 | Cyclophosphamid… Methotrexate Prednisone Leukemia | - - | |||
| NCT03933397 Details | 2023-07-03 Interventional | 3 | 328 | Hydromorphone Morphine Anemia, Sickle … Sickle Cell Dis… | Due to COVID enrollment numbers needed to meet the primary endpoint will not be met. - | |||
| NCT02150967 2013-005085-19 Details | 2023-07-03 Interventional | 2 | 143 | Infigratinib Cholangiocarcin… Advanced Cholan… FGFR2 Gene Muta… | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory
endpoints). Termination was not due to concerns about safety and had no impact on the primary
efficacy analysis (ie, results reported for Cohort 1). - | |||
| NCT05614453 Details | 2023-06-29 Interventional | 2 | 0 | Tislelizumab Uterine Cervica… Metastatic Cerv… | BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing
further development of sitravatinib owing to the negative results of the SAPPHIRE trial which
used sitravatinib in 2nd line met NSCLC setting. - | |||
| NCT04487392 Details | 2023-06-29 Interventional | 2 | 0 | Estrogens Atrophy Vulvovaginal At… | The student do not start the study - | |||
| NCT03126539 Details | 2023-06-29 Interventional | 2 | 9 | Sulforaphane Aging | For administrative reasons, we started a new study - | |||
| NCT02101021 2014-004480-20 Details | 2023-06-29 Interventional | 3 | 25 | Gemcitabine N-(cyanomethyl)… Paclitaxel Adenocarcinoma Metastatic Panc… | - - | |||
| NCT04955574 Details | 2023-06-28 Interventional | 2 | 0 | Anti-Bacterial … Antibiotics, An… Metronidazole Endometriosis Infertility Unexplained Inf… | Change in departmental research focus. - | |||
| NCT04662073 Details | 2023-06-28 Interventional | 2 | 2 | Camostat COVID-19 Covid19 | Enrollment into the camostat subprotocol was halted prematurely as a result of loss of
equipoise due to external findings including those related to monoclonal antibodies. This study did not meet its planned enrollment and did not achieve statistical power as specified in the protocol. | |||
| NCT04639310 2020-002396-35 Details | 2023-06-28 Interventional | 3 | 8 | Ezogabine Brain Diseases Central Nervous… Epilepsy Epileptic Syndr… Nervous System … Seizures Disease Epilepsy in Chi… Epilepsy; Seizu… | Sponsor decision; Not a safety decision - | |||
| NCT04559347 Details | 2023-06-28 Interventional | 2 | - | Bupivacaine Ropivacaine Thoracic Surger… | Reviewing randomization process - | |||
| NCT03805841 Details | 2023-06-28 Interventional | 2 | 41 | Bromides Carcinoma, Non-… EGFR Exon 20 In… ERBB Fusion HER2-activating… NRG1 Fusion NSCLC Stage III… NSCLC, Recurren… NSCLC, Stage II… NSCLC, Stage IV | enrollment pause - | |||
| NCT02519439 Details | 2023-06-28 Interventional | 3 | 26 | Ganaxolone Seizures Drug Resistant … | Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study. Due
to this outcome Marinus discontinued this extension study. - | |||
| NCT02033941 Details | 2023-06-28 Interventional | 2 | - | Phenol Alzheimer Disea… Alzheimer's Dis… | Study has been suspended for the duration of the pandemic. We hope to re-start enrollment later
this year - | |||
| NCT04865029 Details | 2023-06-27 Interventional | 2 | 10 | Estradiol Estradiol 17 be… Estradiol 3-ben… Polyestradiol p… Progesterone COVID-19 Covid19 | Lack of enrollment due to change of COVID 19 variant prevalence Early termination leading to small numbers of subjects analyzed | |||
| NCT04294459 2019-004154-28 Details | 2023-06-27 Interventional | 1/2 | 23 | Acetaminophen Diphenhydramine Methylprednisol… Montelukast Promethazine Ranitidine Immune System D… Immune System D… | Terminated due to non-safety reasons Sponsor decided to terminate the study for non-safety reasons on 02 May 2022. Based on available clinical data at time of interim analysis, it was determined that enrollment of the remaining participants was unlikely to have any significant impact on the study results and hence the trial was stopped. All 23 participants enrolled in the study were followed-up per protocol until the planned study termination date. | |||
| NCT02640534 Details | 2023-06-27 Interventional | 2 | 169 | Metformin Prostatic Neopl… Cancer of the P… Prostate Cancer | The decision is based on the fact that with the current follow up of around 10 years, the
relevant secondary endpoints can adequately be addressed according to protocol. The addition of
follow up data will not significantly impact these results. - | |||
| NCT01307605 2010-021253-39 Details | 2023-06-27 Interventional | 2 | 154 | Lenalidomide Rituximab Lymphoma Lymphoma, Folli… | It was decided by the trial team to stop the collection of follow up data in trial SAKK 35/10. - | |||
| NCT03395314 Details | 2023-06-26 Interventional | 2 | 22 | Ketamine Midazolam Borderline Pers… Personality Dis… | assessment of project in wake of covid-19 related interruptions - | |||
| NCT02932475 Details | 2023-06-26 Interventional | 3 | 831 | Metformin Diabetes Mellit… Pregnancy Compl… Diabetes Pregnancy | Recommendation by the DSMB that the study be stopped for futility - |